top of page

Positive top-line results for romosozumab FRAME study

UCB and Amgen have announced top-line results from the Phase III FRAME study romosozumab in postmenopausal women with osteoporosis. These data showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through months 12 and 24 in postmenopausal women with osteoporosis treated with romosozumab.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page